International Assets Investment Management LLC Reduces Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

International Assets Investment Management LLC lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.6% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 19,833 shares of the biopharmaceutical company’s stock after selling 522 shares during the quarter. International Assets Investment Management LLC’s holdings in Gilead Sciences were worth $1,445,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Tompkins Financial Corp boosted its position in shares of Gilead Sciences by 223.1% during the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 241 shares in the last quarter. Fortitude Family Office LLC purchased a new position in Gilead Sciences in the 4th quarter worth about $29,000. Private Wealth Management Group LLC bought a new position in Gilead Sciences during the fourth quarter valued at approximately $29,000. Sachetta LLC bought a new stake in shares of Gilead Sciences in the fourth quarter worth $30,000. Finally, Rakuten Securities Inc. purchased a new stake in shares of Gilead Sciences during the 4th quarter valued at about $33,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Up 3.2 %

Shares of NASDAQ:GILD opened at $70.67 on Monday. The firm has a market capitalization of $88.04 billion, a PE ratio of 196.31, a price-to-earnings-growth ratio of 1.38 and a beta of 0.20. The business has a 50 day simple moving average of $65.74 and a two-hundred day simple moving average of $72.89. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $87.86. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.08 and a quick ratio of 0.94.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. The company had revenue of $6.69 billion during the quarter, compared to analysts’ expectations of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. Gilead Sciences’s revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.37 EPS. On average, equities analysts predict that Gilead Sciences, Inc. will post 3.75 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be issued a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, June 14th. This represents a $3.08 annualized dividend and a yield of 4.36%. Gilead Sciences’s payout ratio is currently 855.56%.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on GILD shares. Robert W. Baird reiterated a “neutral” rating and set a $80.00 price objective on shares of Gilead Sciences in a research note on Thursday. StockNews.com raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 27th. HSBC raised Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price target on the stock in a report on Wednesday, April 24th. Wells Fargo & Company cut their target price on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a research report on Monday, March 4th. Finally, UBS Group dropped their price target on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. Twelve analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $83.47.

Insider Buying and Selling at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the transaction, the insider now owns 96,304 shares in the company, valued at $7,026,339.84. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.